TULANE UNIVERSITY

Australian-supported research published in The Lancet, JAMA, and JACC reveals GMRx2, a triple combination pill, significantly more effective at controlling hypertension than dual combinations, potentially revolutionising global hypertension management.

Eosinophilic esophagitis (EoE) is an inflammatory disease caused by food and airborne allergens, leading to swallowing difficulties and malnutrition. Tulane researchers identified a protein, IL18, triggering cell release that damages the esophagus, and found a way to stop this process in mice, potentially offering a treatment for EoE.

New Orleans BioInnovation Center announces Informuta as the grand prize winner of the 2024 BioChallenge pitch competition, recognizing its DNA sequencing technology for predicting antibiotic responses. Vaxess and SiVec Biotechnologies won second and third places, respectively, for their vaccine and therapeutic platforms. The competition aligns with NOBIC's mission to develop medical countermeasures for public health threats.

Archaeologists discovered a 4,000-year-old fortified town, al-Natah, in the Khaybar oasis. Dating to 2,400 BC, it housed up to 500 residents and was abandoned around 1,400 BC for unknown reasons. The town featured a 2.6-hectare area with 50 houses on a hill, protected by a wall.

Phase III trial of GMRx2, a triple combination pill for hypertension, published in The Lancet, showed significant BP reduction and improved control rates vs dual therapy, aligning with ESC guidelines. GMRx2, pending FDA approval, could be the first triple combination for initial hypertension treatment.

George Medicines' Phase III trial of GMRx2, a triple combination pill for hypertension, published in The Lancet, showed superior efficacy and safety compared to dual therapies, aligning with ESC guidelines.

Picky eating may signal eosinophilic esophagitis (EOE), an inflammatory disease triggered by food/airborne allergens, causing esophagus shortening/thickening, and food impaction. Tulane researchers identified IL18 protein involvement in EOE pathology.

A fentanyl vaccine developed by University of Houston researchers is expected to enter clinical trials mid-next year, aiming to prevent the opioid from entering the brain and causing overdose. The vaccine, successful in animal studies, is licensed to Ovax, which raised over $10 million for its production and testing. Despite challenges, including lengthy clinical trial processes and stigma around addiction, the vaccine is seen as a potential tool in the fight against the opioid crisis.

George Medicines presents results from two Phase III trials of GMRx2, a novel, low-dose, triple combination pill for hypertension, showing significant BP reduction and improved control rates with good tolerability at ESC Congress 2024.